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Animal studies have shown that central dopamine signaling influences glucose
metabolism. As a first step to show this association in an experimental setting in humans,
we studied whether deep brain stimulation (DBS) of the subthalamic nucleus (STN), which
modulates the basal ganglia circuitry, alters basal endogenous glucose production (EGP)
or insulin sensitivity in patients with Parkinson’s disease (PD). We studied 8 patients with
PD treated with DBS STN, in the basal state and during a hyperinsulinemic euglycemic
clamp using a stable glucose isotope, in the stimulated and non-stimulated condition.
We measured EGP, hepatic insulin sensitivity, peripheral insulin sensitivity (Rd), resting
energy expenditure (REE), glucoregulatory hormones, and Parkinson symptoms, using
the Unified Parkinson’s Disease Rating Scale (UPDRS). Basal plasma glucose and EGP did
not differ between the stimulated and non-stimulated condition. Hepatic insulin sensitivity
was similar in both conditions and there were no significant differences in Rd and plasma
glucoregulatory hormones between DBS on and DBS off. UPDRS was significantly higher
in the non-stimulated condition. DBS of the STN in patients with PD does not influence
basal EGP or insulin sensitivity. These results suggest that acute modulation of the motor
basal ganglia circuitry does not affect glucose metabolism in humans.
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INTRODUCTION
There is ample evidence that the central nervous system (CNS)
regulates glucose homeostasis. In different neural pathways
within the CNS, several neuropeptides and neurotransmitters
have been identified that influence insulin sensitivity (Williams
et al., 2001; Schwartz and Porte, 2005; Sandoval et al., 2009).
Neuromodulation of specific areas of the brain with deep
brain stimulation (DBS) or transcranial direct current stimula-
tion (tDCS) offer unique opportunities to examine the direct role
of the CNS in glucose metabolism. Indeed, it has been shown
that tDCS promotes systemic insulin sensitivity (Binkofski et al.,
2011). DBS of the subthalamic nucleus (STN) is used for the
treatment of Parkinson’s disease (PD) (Krack et al., 2003).
Besides the beneficial effects on Parkinson symptoms, weight
gain is a common side effect of STNDBS and this might be related
to reduced energy expenditure due to decreased locomotor activ-
ity (Rieu et al., 2011), decreased resting energy expenditure (REE)
(Perlemoine et al., 2005) or an increase in energy intake through
an effect on brain areas involved in the regulation of body weight
(Perlemoine et al., 2005). It has been proposed that the STN
DBS-induced current reaches hypothalamic nuclei and hence the
effects on energymetabolismmight be indirect since the hypotha-
lamus controls food intake and energy expenditure (Sauleau et al.,
2009). Furthermore, it has been shown that weight gain is asso-
ciated with the contact site of the electrodes implanted with STN
stimulation, where weight gain is most prominent when the con-
tact sites are in closest relation with the wall of the third ventricle
(Rùžièka et al., 2012). The third ventricle is bounded by the
hypothalamus on both sides.
In addition to food intake and energy expenditure, the
hypothalamus is involved in the regulation of glucose metabolism
and insulin sensitivity (Obici et al., 2002; Kalsbeek et al., 2004;
Yi et al., 2010) and STN DBS might therefore also affect glucose
fluxes. Studies on glucose metabolism in patients with PD and
DBS are scarce. One study showed a reduction in endogenous
glucose production (EGP) with STN DBS (Batisse-Lignier et al.,
2013).
STN DBS modulates the basal ganglia circuitry, where it exerts
differential effects on different nuclei (Meissner et al., 2005; Reese
et al., 2011). It has been postulated that STN DBS also acti-
vates surviving nigrostriatal neurons projecting to the striatum
and thereby changing local dopamine concentrations (Marani
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et al., 2008). Several studies in animals have shown an increase
in striatal dopamine with STN DBS (Meissner et al., 2003; Shon
et al., 2010). Dopamine is known to be involved in glucose
metabolism since dopamine antagonists induce insulin resistance
in clinical studies, while dopamine agonists improve glucose
intolerance (Pijl et al., 2000; Liebzeit et al., 2001). This seems at
least in part to be a centrally regulated effect while drug naïve
schizophrenic patients, who have a disturbed central dopamin-
ergic homeostasis, display hepatic insulin resistance compared
to healthy controls (Van Nimwegen et al., 2008). Furthermore,
animal studies revealed that icv bromocriptine has an effect on
glucose metabolism (Luo et al., 1999). In humans, the direct role
of central dopamine in the regulation of glucose metabolism and
insulin sensitivity is unknown.
We aimed to investigate the effects of STN DBS on glucose
metabolism and insulin sensitivity and measured basal glucose
metabolism and insulin sensitivity, using a hyperinsulinemic eug-
lycemic clampwith a stable glucose isotope tracer, in patients with
PD and DBS of the STN in the stimulated and non-stimulated
condition.
MATERIALS AND METHODS
PATIENTS
We included men with stable PD, treated with bilateral DBS of
the STN. Patients were recruited from the Outpatient Clinic of
the Department of Neurology of the Academic Medical Center,
Amsterdam, the Netherlands. Exclusion criteria were: age below
18 years, other functional stereotactic neurosurgical interven-
tions (e.g., pallidotomy), unstable weight, psychosis, depression,
alcoholism, dyslipidemia (primary or secondary form), use of
lipid lowering drugs, use of medication influencing glucose
metabolism, (except dopamine agonists), type II diabetes mellitus
(DM), first degree family member with type II DM, active smok-
ing, renal insufficiency (creatinine>150μmol/L) or elevated liver
enzymes.
This study was approved by the institutional review board
of the Academic Medical Center. Written informed consent was
received from all patients prior to inclusion and after the purpose
of the study was described.
HYPERINSULINEMIC EUGLYCEMIC CLAMP
[6,6-2H2]glucose (>99% enriched; Cambridge Isotopes,
Andover, USA) was used to measure EGP based on the principle
of the isotope dilution technique.
After an overnight fast the patients were admitted at the
Metabolic Unit at 0830 h. For the infusion of stable isotope tracer,
insulin, and glucose, a catheter was placed into an antecubital
vein of the left hand. For drawing arterialized venous blood
another catheter was inserted into a vein of the right hand and
kept into a thermo-regulated (60◦C) plexiglas box. Saline (NaCl
0.9%) was infused at a rate of 50ml/h to sustain catheter patency.
Before the start of the clamp, at T = 0 (0900 h), blood sam-
ples for background enrichment were taken, whereafter a primed
continuous infusion of a stable glucose isotope was started ([6,6-
2H2]glucose at a rate of 0.11μmol/kg·min, with a priming dose
of 8.8μmol/kg) and continued during the study day. After a
2 h-equilibration period, blood samples were drawn for isotope
enrichments and glucoregulatory hormones. Thereafter, the DBS
remained either in the on situation or was turned off. This was
done in a single blinded way, in random assignment, by the treat-
ing neurologist not otherwise involved in the tests. The researcher
performing the clampwas not aware of the on or off situation. For
the next 3.5 h, blood samples were taken every 30min for isotope
enrichments and glucoregulatory hormones.
Next, a 1-step hyperinsulinemic euglycemic clamp was started,
with a continuous infusion of insulin (Actrapid 100U/ml; Novo
Nordisk Farma, Alphen a/d Rijn, the Netherlands) for 2 h and
10min (20mU/m2 body surface area min). Every 5min, plasma
glucose concentrations were determined and to maintain a
plasma glucose level of 5.0mmol/L, a solution of glucose 20%was
infused at a variable rate. Within this solution 1% was enriched
with [6,6-2H2]Glucose to approximate the enrichment values
in plasma and thereby minimize alterations in isotopic enrich-
ment due to the infusion of exogenous glucose (Finegood et al.,
1987). During the last 25min of the hyperinsulinemic period, five
blood samples were drawn at 5-min intervals for determination of
isotope enrichments and glucoregulatory hormones. During the
study, the patients were allowed to drink water only.
Within 1 month the same study day was performed with the
DBS electrodes either switched on or off (random assignment).
BODY COMPOSITION AND INDIRECT CALORIMETRY
Body composition was measured at the beginning of both study
days using bioelectrical impedance analysis (Maltron BF906;
Maltron, Rayleigh, UK).
Oxygen consumption (VO2)and CO2 production (VCO2)
were measured continuously during 20min of every hour of the
first 3 h and during the final 20min of the hyperinsulinemic eug-
lycemic clamp by indirect calorimetry using a ventilated hood
system (Sensormedics model 2900; Sensormedics, Anaheim,CA).
The mean values of VO2 and VCO2 were used for the calculation
of glucose and fat oxidation.
UNIFIED PARKINSON’S DISEASE RATING SCALE
Every hour, Parkinson symptoms were assessed with the Unified
Parkinson’s disease Rating Scale (UPDRS) motor section (Gelb
et al., 1999) by a specialized PD nurse that was blinded for the
DBS settings (on vs. off). The UPDRS is widely used for the clin-
ical evaluation of PD. A higher score denotes more severe PD
symptoms (0 = no symptoms, 108 = worst score).
ANALYTICAL PROCEDURES
With the use of a Biosen C-line plus glucose analyzer (EKF
Diagnostics, Barbleben/Magdeburg, Germany), plasma glucose
levels were determined (the glucose oxidase method). [6,6-
2H2]Glucose enrichment was measured as described earlier
(intraassay variation: 0.5–1%, interassay variation: 1%, detec-
tion limit: 0.04%) (Ackermans et al., 2001). Plasma levels of
insulin and cortisol were measured using the Immulite 2000
system (Diagnostic Products Corp., Los Angeles, CA) (insulin;
intraassay variation: 3–6%, interassay variation: 4–6%, detec-
tion limit: 15 pmol/l and cortisol; intraassay variation: 7–8%,
interassay variation: 7–8%, detection limit: 50 nmol/l).Plasma
glucagon concentrations were measured with the Linco 125I
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RIA (Linco Research,St. Charles, MO) (intraassay variation:
9–10%,interassay variation: 5–7%, detection limit: 15 ng/l).
CALCULATIONS AND STATISTICS
EGP was calculated using the modified forms of the Steele
Equations as described previously (Steele, 1959; Finegood et al.,
1987). O2 consumption and CO2 production were used to calcu-
late REE, glucose- and fat oxidation rates, as reported previously
(Frayn, 1983).
SPSS version 18.0 (SPSS,Chicago, IL, USA) was used for sta-
tistical analysis. If measured values were below limit of detection,
for the calculations half of the limit of detection value was used.
To investigate the influence of DBS on basal EGP, glucose,
glucoregulatory hormones, and REE, linear mixed-effect mod-
els were used to analyze group differences during the first 3.5 h
after start of the intervention. Baseline values as confounding fac-
tor were included in the model as covariates. The dependency of
the measurements within the same subject was accounted for by
including subject-specific variables. Different covariance struc-
tures were explored, and the model with the best fit was used.
Interaction terms between groups and group and time-points
were used to examine group related differences between the stim-
ulated and non-stimulated condition. For each of the models, the
residuals were normally distributed (Wilk-Shapiro’s W > 0.90)
and showed constant variance. Comparison of the clamp data
within subjects,between the stimulated and non-stimulated con-
dition, were done using the Wilcoxon signs rank test.A p-value
of < 0.05 was considered statistically significant and a p-value of
< 0.1 was considered as a trend. Data are presented as median
(minimum–maximum) or median ± s.e.m.
RESULTS
PATIENT CHARACTERISTICS
We included 8men who were diagnosed with PD and treated with
bilateral STN DBS. Their baseline characteristics are summarized
in Table 1. One patient only completed the first study day due to
medical problems not related to this study.
As for the use of dopaminergic medication: all patients were
on levodopa, with an average dose of 4 × 125mg/day. Four
patients also used D2 dopamine agonists, 7mg/day on average.
The patients took their dopaminergic medication at exactly the
same time on both study days.
BASAL GLUCOSE METABOLISM
During the first 3.5 h, basal EGP did not differ between the stimu-
lated and non-stimulated condition (Figure 1A). Plasma glucose
Table 1 | Patient characteristics.
PATIENT CHARACTERISTICS
Age (years) 59 [44–65]
Height (cm) 183.5 [173–189]
Weight (kg) 88.5 [67.9–118.6]
BMI (kg/m2) 26.45 [22.7–33.2]
Fat mass (%) 31.65 [21.0–39.0]
Lean mass (%) 68.35 [53.7–71.8]
Data expressed as median [min-max].
and plasma insulin during the first 3.5 h levels were comparable
between the two study days (Figures 1B,C).
INSULIN SENSITIVITY
There were no significant differences in plasma concentrations
of glucose or insulin during the hyperinsulinemic euglycemic
clamps on both study days (Table 2). Insulin-mediated suppres-
sion of EGP, expressed as the percentage of basal EGP, was similar
in both conditions (stimulated 77.8 [68–97]% vs. non-stimulated
76 [71–97] %, p = 0.866) (Figure 2). BMI negatively correlated
with hepatic insulin sensitivity (data not shown). Glucose rate
of disappearance (Rd) was not significantly different between the
two study days (stimulated 14.82 [9.51–21.96] vs. non-stimulated
14.24 [9.06–14.64]μmol/kg.min, p = 0.128).
GLUCOREGULATORY HORMONES
There were no differences in glucoregulatory hormones neither
in the basal state nor during the hyperinsulinemic euglycemic
clamp, between the stimulated and the non-stimulated condition
(Figures 1D–G, Table 2).
INDIRECT CALORIMETRY AND UPDRS
There were significant differences in REE during the first 3 h
between the stimulated and non-stimulated condition. DBS∗time
interaction significantly differed between the 2 groups, p = 0.018
(Figure 1H) but DBS∗group interaction was not significant, sug-
gesting that DBS did not affect basal REE.
During the hyperinsulinemic euglycemic clamp, REE was sig-
nificantly higher in the non-stimulated condition (REE with
DBS on 1718 [1292–1887] vs. with DBS off 1850 [1352–
2030] kcal/24 h, p = 0.043) (Table 2), although not significantly
different when expressed as percentage increase from basal REE.
No differences were found in respiratory quotient (RQ),
glucose-, and fat oxidation rates, in the basal state nor in the
hyperinsulinemic state (data not shown).
As expected, Parkinson symptoms measured by the UPDRS,
were significantly higher when the DBS was switched off during
the entire study day (p = 0.022, Figure 1I).
DISCUSSION
We show that STN DBS, in patients with stable PD, does not
have an acute effect on basal EGP, hepatic or peripheral insulin
sensitivity, nor on basal plasma concentrations of glucose and
insulin. Furthermore, STN DBS does not have an effect on other
glucoregulatory hormones.
Our results seem in contrast with an earlier report on lower
EGP upon STN DBS, i.e., Batisse-Lignier et al showed that basal
EGP was decreased in the stimulated condition (Batisse-Lignier
et al., 2013). However, the 22% decrease in EGP in that study
could alternatively be explained by the physiological adaptation
to fasting since EGP was measured in both the non-stimulated
and stimulated condition, consecutively on one study day, and
thus with a difference in hours of fasting. In fact, the median
decrease in EGP in our patients over time was 24% and compara-
ble between the on and the off situation (Figure 1A), representing
a physiological decrease in EGP during prolonged fasting.
In our study, there were no significant changes in REE,
which could be attributed to the DBS itself. Also, we found no
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FIGURE 1 | Basal EGP (A), plasma glucose (B), glucoregulatory hormones (C–G), REE (H), and UPDRS (I). DBS switched on (•) and switched off (). Data
are expressed as median ± s.e.m. ∗p < 0.05.
correlation between PD symptoms and REE (data not shown).
Regulation of basal energy expenditure strongly depends on
hypothalamic control and hypothalamic integration of metabolic
signals. Whether these neuronal pathways are different in the
stimulated vs. non-stimulated condition is unknown. Long-term
studies on energy expenditure in STN DBS treated patients
however, all show a decrease in basal and total energy expendi-
ture (decrease of approximately 10%), which in some studies is
also explained by a reduction in muscle tone (Rieu et al., 2011).
During hyperinsulinemia, REE was significantly lower in the
stimulated condition, but when expressed as percentage increase
from basal REE these differences were no longer apparent. This
suggests that the increase in REE induced by metabolic handling
of the infused glucose is not affected by DBS of the STN.
Anatomically, the STN receives input from the globus pal-
lidus and sends excitatory projections to the globus pallidus and
the basal ganglia. PD is characterized by a progressive loss of
nigrostriatal dopaminergic neurons and consequently leads to a
reduced globus pallidus output and an activated discharge from
the STN to the basal ganglia. STN DBS modulates the basal
ganglia circuitry, where it exerts differential effects on different
nuclei. For instance, it has been shown that STN DBS decreases
STN activity and enhances pallidal firing rate (Meissner et al.,
2005; Reese et al., 2011), with a subsequent altered basal gan-
glia output. However, not all mechanisms by which STN DBS
decreases Parkinson symptoms have been clarified yet. It has
been proposed by some researchers that STN DBS also acti-
vates surviving nigrostriatal neurons projecting to the striatum,
probably via STN—substantia nigra pars compacta connections
(Marani et al., 2008) and thereby changes local dopamine con-
centrations. Indeed, in studies in rodents and pigs it has been
shown that STN DBS increases striatal dopamine (Meissner et al.,
2003; Shon et al., 2010). And although results of studies on STN
DBS on striatal dopamine remain controversial, Yamamoto et al
showed a significant correlation between STN activity and stri-
atal monoamine concentrations in the normal and the PD rat
(Yamamoto et al., 2013). We therefore hypothesized that STN
DBS in humans would alter striatal dopamine and could influ-
ence glucose metabolism via dopaminergic pathways. However,
whether striatal dopamine increases upon STN DBS in humans
is unclear. Hilker et al could not demonstrate an increase in stri-
atal dopamine release in Parkinson patients with STN DBS using
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FIGURE 2 | Hepatic insulin sensitivity. DBS switched on (•) and switched
off (), p = 0.866.
Table 2 | Clamp measurements.
On Off p
HYPERINSULINEMIC EUGLYCEMIC CLAMP
Glucose (mmol/L) 5.09 [4.8–5.21] 5.01 [4.92–5.13] 0.753
EGP (μmol/kgLBM·min) 3.40 [0.51–5.31] 3.37 [0.44–5.19] 0.866
Insulin (pmol/L) 191 [149–283] 191 [167–244] 0.176
Glucagon (ng/L) 40 [20–54] 37 [29–62] 0.127
Cortisol (nmol/L) 213 [121–306] 281 [141–342] 0.398
REE (kcal/day) 1718 [1292–1887] 1850 [1352–2030] 0.043
Data are expressed as median [min-max].
positron emission tomography with the dopamine D2/3-receptor
ligand [11C]raclopride (Hilker et al., 2008). Although, it is known
that with this technique, small changes in dopamine cannot
be detected. Another explanation for the lack of a metabolic
effect could be that the changes in striatal dopamine observed in
animals cannot be directly translated to the human situation.
Finally, it could be that in our study, dopamine changes
within the striatum were not extensive enough to alter glucose
metabolism, and that there is a certain threshold needed to exert
an effect. Indeed, pig studies showed a dose effect curve on
dopamine release, which was intensity- and frequency- depen-
dent (Shon et al., 2010). Our patients remained on their levodopa
medication during both study days because they had clinical
benefit from this treatment and the medication could not be
discontinued on ethical grounds. This might have disguised any
additional effects of the STN DBS and we cannot fully exclude
possible influences of their medication, however, to minimize
possible interference with our study results, the patients took their
medication at the same time points on both study days, and the
patients served as their own controls. It is not known whether
the earlier described beneficial effects of dopamine agonists on
glucose metabolism in humans (Pijl et al., 2000) occur via central
or peripheral mechanisms.
It has been proposed that gamma-aminobutyric acid (GABA)
could also mediate the beneficial effects on locomotor symptoms
of STN DBS in Parkinson patients, because in rats stimulated
with DBS in the STN, extracellular GABA is increased besides
dopamine (Windels et al., 2000, 2003) and thus a combination
of an increase in dopamine and GABA release might be respon-
sible for the observed effects. It has been argued that this change
in GABA is related to reducing of pathological hyperactivity in
output structures of the STN. There is however no evidence that
this would also result in changes in activity in hypothalamic areas
involved in the regulation of glucose metabolism. It is clear from
our data though, that whether dopamine and/or GABA are altered
in Parkinson patients treated with STN-DBS (or not), stimulation
does not result in acute changes in glucose metabolism.
In our study, wemeasured acute effects of STNDBS on glucose
metabolism and insulin sensitivity. Long-term effects of DBS STN
on these parameters are unknown. It has been suggested that PD
in itself is associated with the occurrence of diabetes (Skeie et al.,
2013). Studies show that patients with PD display a dopaminer-
gic dysfunction in the hypothalamus (Politis et al., 2008), which
might contribute to the development of endocrine disorders asso-
ciated with this disease. The occurrence of type II diabetes in
patients with DBS of the STN however, is difficult to interpret,
because most of these patients gain weight/fat mass after place-
ment of the DBS (Barichella et al., 2003; Montaurier et al., 2007;
Bannier et al., 2009), which might disguise any favorable effect
of the DBS itself. Furthermore, most patients also decrease their
levodopa medication after DBS placement.
CONCLUSION
DBS of the STN in patients with PD does not have an acute effect
on basal glucose metabolism nor on insulin sensitivity. These
results suggest that modulation of the basal ganglia circuitry does
not affect glucose metabolism in humans. Part of the lack of
the effect might be explained by the concurrent use of levodopa
medication.
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